Weekly Recap | Gilead Sciences +4.44%, most brokers rate it buyWeekly Review·Oct 10, 2026 at 06:37 AMGILD+2.49%
Weekly Recap | Gilead Sciences -4.1%, sliding toward range lowsWeekly Review·Oct 3, 2026 at 06:52 AMGILD+2.49%
Weekly Recap | Gilead Sciences +0.55%, consensus target above spotWeekly Review·Sep 26, 2026 at 06:25 AMGILD+2.49%
Weekly Recap | Gilead Sciences +4.45%, consensus target above spotWeekly Review·Sep 19, 2026 at 06:04 AMGILD+2.49%
Weekly Recap | Gilead Sciences -4.82%, most brokers rate it buyWeekly Review·Sep 12, 2026 at 08:16 AMGILD+2.49%
Weekly Recap | Gilead Sciences +3.65%, FDA approves new HIV tabletWeekly Review·Sep 5, 2026 at 07:02 AMGILD+2.49%
Weekly Recap | Gilead Sciences -0.3%, FDA approves once-daily HIV pillWeekly Review·Aug 29, 2026 at 05:38 AMGILD+2.49%
